ENTX

SEC source: 0001178913-25-000156 · ownership.xml · nonDerivative · entry 1

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 276,208

F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.

SEC source: 0001178913-25-000158 · ownership.xml · derivative · entry 2

OSTROV GERALD M · CIK 0001534739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,509

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 28,509 shares

Expires 2035-01-15

F2 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2025.

SEC source: 0001178913-25-000158 · ownership.xml · nonDerivative · entry 1

OSTROV GERALD M · CIK 0001534739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 46,936

F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.

SEC source: 0001178913-25-000159 · ownership.xml · derivative · entry 2

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,509

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 28,509 shares

Expires 2035-01-15

F2 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2025.

SEC source: 0001178913-25-000159 · ownership.xml · nonDerivative · entry 1

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,650

F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.

SEC source: 0001178913-25-000157 · ownership.xml · derivative · entry 2

Malca Yonatan · CIK 0001904759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,509

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 28,509 shares

Expires 2035-01-15

F2 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2025.

SEC source: 0001178913-25-000157 · ownership.xml · nonDerivative · entry 1

Malca Yonatan · CIK 0001904759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 47,259

F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.

SEC source: 0001178913-25-000155 · ownership.xml · derivative · entry 2

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 28,509

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 28,509 shares

Expires 2035-01-15

F2 · derivative.exercise_date: These options represent the Board's annual grant of options to directors of the Company. The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2025.

SEC source: 0001178913-25-000155 · ownership.xml · nonDerivative · entry 1

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 134,727

F1 · kind: The Board of Directors ("Board") of Entera Bio Ltd. (the "Company") awarded these shares to the Reporting Persons in lieu of the cash fees the Reported Person was entitled to for services rendered as a director of the Company for the fourth quarter of 2024.

SEC source: 0001178913-24-003216 · ownership.xml · nonDerivative · entry 1

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 265,491

SEC source: 0001178913-24-003220 · ownership.xml · nonDerivative · entry 1

OSTROV GERALD M · CIK 0001534739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 38,898

SEC source: 0001178913-24-003222 · ownership.xml · nonDerivative · entry 1

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,728

SEC source: 0001178913-24-003218 · ownership.xml · nonDerivative · entry 1

Malca Yonatan · CIK 0001904759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,043

SEC source: 0001178913-24-003214 · ownership.xml · nonDerivative · entry 1

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 127,627

SEC source: 0001178913-24-002887 · ownership.xml · nonDerivative · entry 1

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 254,222

SEC source: 0001178913-24-002897 · ownership.xml · nonDerivative · entry 1

OSTROV GERALD M · CIK 0001534739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,446

SEC source: 0001178913-24-002895 · ownership.xml · nonDerivative · entry 1

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 50,450

SEC source: 0001178913-24-002893 · ownership.xml · nonDerivative · entry 1

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 120,161

SEC source: 0001178913-24-002889 · ownership.xml · nonDerivative · entry 1

Malca Yonatan · CIK 0001904759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,404

SEC source: 0001178913-24-002391 · zk2431765.xml · derivative · entry 2

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 500,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 500,000 shares

Expires 2034-04-19

F2 · derivative.exercise_date: This grant of options was approved by the Board on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The options vest over a three-year period that commenced on April 19, 2024, with a third of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

SEC source: 0001178913-24-002391 · zk2431765.xml · nonDerivative · entry 1

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 234,873

F1 · price: Represent a grant of stock-settled restricted stock units. This grant of stock-settled restricted stock units was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 19, 2024, subject to approval by the Company's shareholders, which was obtained on July 31, 2024. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.

SEC source: 0001178913-24-001423 · ownership.xml · derivative · entry 2

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 130,000 shares

Expires 2034-04-19

F2 · derivative.exercise_date: The options vest over a three-year period with 33% of the options vesting on April 19, 2025, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

SEC source: 0001178913-24-001423 · ownership.xml · nonDerivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,731

F1 · price: Represent a grant of stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.

SEC source: 0001178913-24-001421 · ownership.xml · derivative · entry 2

Galitzer Hillel · CIK 0001904740 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 130,000 shares

Expires 2034-04-19

F2 · derivative.exercise_date: The options vest over a three-year period with 33% of the options vesting on April 19, 2025, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

SEC source: 0001178913-24-001421 · ownership.xml · nonDerivative · entry 1

Galitzer Hillel · CIK 0001904740 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,257

F1 · price: Represent a grant of stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.

SEC source: 0001178913-24-002392 · ownership.xml · derivative · entry 2

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 130,000 shares

Expires 2034-04-19

F4 · derivative.exercise_date: The options vest over a three-year period with 33% of the options vesting on April 19, 2025, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.

SEC source: 0001178913-24-002392 · ownership.xml · nonDerivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By A2Z Counseling Ltd.

Disclosed balance after: 86,731

F1 · price: Represent a grant of stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.

F2 · ownership.direct: On April 23, 2024, the reporting person filed a Form 4 which inadvertently reported that the reporting person's ordinary shares and restricted stock units are held directly.

F3 · ownership.nature: These shares are owned by A2Z Counseling Ltd. of which the reporting person owns a 33.33% interest and has effective control over voting and disposition of the shares. The reporting person disclaims beneficial ownership of the securities held by A2Z Counseling Ltd., except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that she is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC source: 0001178913-24-000164 · zk2430779.xml · nonDerivative · entry 1

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,115

SEC source: 0001178913-24-000135 · zk2430773.xml · nonDerivative · entry 1

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,615

SEC source: 0001178913-24-000055 · zk2430736.xml · derivative · entry 1

GARCEAU ROGER · CIK 0001451767 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,333

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 108,333 shares

Expires 2034-01-01

F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024.

SEC source: 0001178913-24-000047 · zk2430732.xml · derivative · entry 1

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,333

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 108,333 shares

Expires 2034-01-01

F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024.

SEC source: 0001178913-24-000051 · zk2430734.xml · derivative · entry 1

OSTROV GERALD M · CIK 0001534739 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,333

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 108,333 shares

Expires 2034-01-01

F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024.

SEC source: 0001178913-24-000060 · zk2430737.xml · derivative · entry 1

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,333

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 108,333 shares

Expires 2034-01-01

F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024.

SEC source: 0001178913-24-000053 · zk2430735.xml · derivative · entry 1

Malca Yonatan · CIK 0001904759 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,333

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 108,333 shares

Expires 2034-01-01

F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024.

SEC source: 0001178913-24-000049 · zk2430733.xml · derivative · entry 1

Mayron Ron · CIK 0001722033 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,333

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 108,333 shares

Expires 2034-01-01

F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024.

SEC source: 0001178913-24-000045 · zk2430731.xml · derivative · entry 1

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 108,333

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 108,333 shares

Expires 2034-01-01

F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 1, 2024.

SEC source: 0001178913-23-003971 · zk2330699.xml · derivative · entry 2

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,952

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 23,952 shares

Expires 2028-12-22

F1 · derivative.exercise_price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules.

F1 · price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules.

SEC source: 0001178913-23-003971 · zk2330699.xml · nonDerivative · entry 1

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 110,752

F1 · price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules.

SEC source: 0001178913-23-003988 · zk2330700.xml · derivative · entry 6

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,952

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 23,952 shares

Expires 2028-12-22

F1 · derivative.exercise_price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules.

F1 · price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules.

SEC source: 0001178913-23-003988 · zk2330700.xml · nonDerivative · entry 1

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 226,961

F1 · price: The Reporting Person entered into a Securities Purchase Agreement with the Issuer on December 20, 2023, pursuant to which, on December 22, 2023, the Reporting Person acquired an aggregate of 23,952 units for a purchase price of $0.835 per unit, each unit consisting of one share of the Issuer's ordinary shares, par value NIS 0.0000769 per share ("Ordinary Shares"), and one warrant, exercisable to purchase an Ordinary Share at an exercise price of $1.00 per share. The purchase price for each unit included $0.125 for the warrant in accordance with Nasdaq rules.

F2 · balance_after: The Reporting Person's aggregate amount of Ordinary Shares in the Reporting Person's previous filings was inadvertently overstated by 11,200 shares. The aggregate amount has been properly adjusted in this Form 4.

SEC source: 0001178913-23-003156 · zk2330299.xml · derivative · entry 1

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 350,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 350,000 shares

Expires 2033-04-24

F1 · derivative.exercise_date: This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on April 24, 2023, subject to approval by the Company's shareholders, which was obtained on September 13, 2023. The options vest over a four-year period that commenced on April 24, 2023, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

SEC source: 0001178913-23-003157 · zk2330300.xml · derivative · entry 1

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,368

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 33,368 shares

Expires 2033-06-06

F1 · derivative.exercise_date: This grant of options was approved by the Board of Directors (the "Board") of Entera Bio Ltd. (the "Company") on June 6, 2023, subject to approval by the Company's shareholders, which was obtained on September 13, 2023. The options vest ratably on an annual basis over a three-year period that commenced on June 6, 2023.

SEC source: 0001178913-23-002985 · ownership.xml · nonDerivative · entry 1

Taitel Haya · CIK 0001979599 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,000

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.619 to $0.626, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001178913-23-002957 · zk2330211.xml · nonDerivative · entry 1

Ellis Sean · CIK 0001904752 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,100

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.5999 to $0.6074, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001178913-23-002974 · zk2330218.xml · nonDerivative · entry 1

LIEBERMAN GERALD M · CIK 0001234346 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,209

SEC source: 0001178913-23-001532 · ownership.xml · derivative · entry 1

Santora Arthur C II · CIK 0001904746 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 35,000 shares

Expires 2033-04-24

F1 · derivative.exercise_date: The options vest over a four-year period with 25% of the options vesting on April 24, 2024, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

SEC source: 0001178913-23-001531 · zk2329588.xml · derivative · entry 1

Yaacov-Garbeli Dana · CIK 0001909822 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 190,000 shares

Expires 2033-04-24

F1 · derivative.exercise_date: The options vest over a four-year period with 25% of the options vesting on April 24, 2024, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

SEC source: 0001178913-23-001530 · ownership.xml · derivative · entry 1

Galitzer Hillel · CIK 0001904740 · Chief Operating Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 210,000

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 210,000 shares

Expires 2033-04-24

F1 · derivative.exercise_date: The options vest over a four-year period with 25% of the options vesting on April 24, 2024, the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.

SEC source: 0001178913-23-001348 · zk2329512.xml · nonDerivative · entry 1

Toledano Miranda Jayne · CIK 0001686530 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 86,800

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.4976 to $0.55, inclusive. The reporting person undertakes to provide to Entera Bio Ltd., an Israeli company ("Entera Bio"), any security holder of Entera Bio, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

SEC source: 0001178913-23-000055 · zk2328964.xml · derivative · entry 1

GARCEAU ROGER · CIK 0001451767 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 89,041

Underlying: Ordinary Shares, par value NIS 0.0000769 per share · 89,041 shares

Expires 2033-01-02

F1 · derivative.exercise_date: The options vest ratably on a quarterly basis over a one-year period that commenced on January 2, 2023.